Varnai, R.; Molnar, T.; Zavori, L.; Tőkés-Füzesi, M.; Illes, Z.; Kanizsai, A.; Csecsei, P.
Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. Vaccines 2022, 10, 165.
https://doi.org/10.3390/vaccines10020165
AMA Style
Varnai R, Molnar T, Zavori L, Tőkés-Füzesi M, Illes Z, Kanizsai A, Csecsei P.
Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. Vaccines. 2022; 10(2):165.
https://doi.org/10.3390/vaccines10020165
Chicago/Turabian Style
Varnai, Reka, Tihamer Molnar, Laszlo Zavori, Margit Tőkés-Füzesi, Zsolt Illes, Andrea Kanizsai, and Peter Csecsei.
2022. "Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms" Vaccines 10, no. 2: 165.
https://doi.org/10.3390/vaccines10020165
APA Style
Varnai, R., Molnar, T., Zavori, L., Tőkés-Füzesi, M., Illes, Z., Kanizsai, A., & Csecsei, P.
(2022). Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. Vaccines, 10(2), 165.
https://doi.org/10.3390/vaccines10020165